<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00568997</url>
  </required_header>
  <id_info>
    <org_study_id>CASM981C2311</org_study_id>
    <nct_id>NCT00568997</nct_id>
  </id_info>
  <brief_title>10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus</brief_title>
  <acronym>PEER</acronym>
  <official_title>A Prospective 10 Year Observational Registry of Pediatric Subjects (Age Greater Than or Equal to Two Years to Age Less Than or Equal to 17 Years) With Atopic Dermatitis Who Have Used Elidel Cream 1% (Pimecrolimus)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valeant Pharmaceuticals International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical Research Computing Unit (University of Pennsylvania)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Valeant Pharmaceuticals International, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the risk of systemic malignancies in pediatric patients with atopic
      dermatitis exposed to Elidel 1% cream.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Registry study to examine the risk of systemic malignancies in pediatric patients with atopic
      dermatitis exposed to Elidel 1% cream.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 27, 2005</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence rate of systemic malignancies in pediatric subjects with atopic dermatitis who have been exposed to pimecrolimus 1% cream</measure>
    <time_frame>10 years of observation with 6-month reporting intervals</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence rate of lymphoma in pediatric subjects with atopic dermatitis who have been exposed to pimecrolimus 1% cream</measure>
    <time_frame>10 years of observation with 6-month reporting intervals</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence rate of thyroid cancer in pediatric subjects with atopic dermatitis who have been exposed to pimecrolimus 1% cream</measure>
    <time_frame>10 years of observation with 6-month reporting intervals</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence rate of cutaneous malignancy in pediatric subjects with atopic dermatitis who have been exposed to pimecrolimus 1% cream</measure>
    <time_frame>10 years of observation with 6-month reporting intervals</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">8000</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Single-group Open Label Registry of patients exposed to Elidel/Pimecrolimus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pimecrolimus</intervention_name>
    <description>Pimecrolimus 1% cream</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Elidel</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Children (ages 2-17 years)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  males and females

          -  greater than or equal to 2 years and less than or equal to 17 years at enrollment

          -  diagnosis of atopic dermatitis (confirmed by treating physician)

          -  applied pimecrolimus cream 1 % 6 weeks out of past 24 weeks

        Exclusion Criteria:

          -  past or present history of systemic malignancy, skin malignancy, or
             lymphoproliferative disease

          -  past or present use of oral immunosuppressive therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Valeant Pharmaceuticals</last_name>
    <phone>908-927-1400</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Johnson Varughese</last_name>
    <phone>908-927-1162</phone>
    <email>johnson.varughese@valent.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Registry</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NA NA</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2007</study_first_submitted>
  <study_first_submitted_qc>December 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2007</study_first_posted>
  <last_update_submitted>December 8, 2017</last_update_submitted>
  <last_update_submitted_qc>December 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atopic dermatitis eczema pediatric pimecrolimus malignancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pimecrolimus</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

